| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/26/2009 | US7537764 E-protein specific immunoglobulin for use in treatment and prevention of viral infection |
| 05/26/2009 | US7537763 Tumor necrosis factor specific immunoglobulin for use in treatment and prevention of tumor disorder; tissue targeted therapy |
| 05/26/2009 | US7537762 Human monoclonal antibodies to activin receptor-like kinase-1 |
| 05/26/2009 | US7537761 Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| 05/26/2009 | US7537760 Monoclonal antibodies recognizing BAG3 protein sequences and their use in diagnostic and therapy of cell death-involving diseases |
| 05/26/2009 | US7537759 Modulating angiogenesis |
| 05/26/2009 | US7537758 Antibodies against a peptide epitope of apolipoprotein B |
| 05/26/2009 | US7537757 Administering an antibody that specifically binds to EMAP(endothelial monocyte-activating polypeptides II) to the subject which needs inhibition of EMAP activity in an amount effective to stimulate vascular growth in cardiac muscle |
| 05/26/2009 | US7537756 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 05/26/2009 | CA2497857C Novel p-selectin ligand protein |
| 05/26/2009 | CA2393072C Mono- and disaccharide derivatives |
| 05/26/2009 | CA2284541C Detoxified mutants of bacterial adp-ribosylating toxins as parenteral adjuvants |
| 05/26/2009 | CA2141022C Allergen of cladosporium herbarum |
| 05/22/2009 | WO2009065121A1 Increased stability of a dna formulation by including poly-l-glutamate |
| 05/22/2009 | WO2009065098A1 Use of cathepsin k antagonists in the treatment of bone cancer |
| 05/22/2009 | WO2009065032A1 Antibody production elicited by a dna vaccine delivered by electroporation |
| 05/22/2009 | WO2009064944A2 Antibodies to lrp6 |
| 05/22/2009 | WO2009064913A1 Chimer containing a targeting portion linked to a scission-activated duocarmycin-type prodrug |
| 05/22/2009 | WO2009064854A2 Humanized antibodies against tl1a |
| 05/22/2009 | WO2009064838A1 Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
| 05/22/2009 | WO2009064825A2 Bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection |
| 05/22/2009 | WO2009064805A1 Compositions and methods for the therapy and diagnosis of influenza |
| 05/22/2009 | WO2009063995A1 Diagnosis and treatment of arteriosclerosis |
| 05/22/2009 | WO2009063970A1 Diagnosis and treatment of cancer using anti-gpr49 antibody |
| 05/22/2009 | WO2009063965A1 Monoclonal antibody capable of binding to anexelekto, and use thereof |
| 05/22/2009 | WO2009063507A1 Dna vaccine against anthrax |
| 05/22/2009 | WO2009063461A1 Methods of treating cancer using anti cd24 antibodies |
| 05/22/2009 | WO2009063241A1 3-hydroxyanthranilic acid or salts thereof1 for treating cancer or infections |
| 05/22/2009 | WO2009062960A1 Formulations for taci-immunoglobulin fusion proteins |
| 05/22/2009 | WO2009062926A1 Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
| 05/22/2009 | WO2009062916A1 Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
| 05/22/2009 | WO2009062690A1 Axl antibodies |
| 05/22/2009 | WO2009062532A1 Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains |
| 05/22/2009 | WO2009062309A1 Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
| 05/22/2009 | WO2009062238A1 Epitope for neutralizing antibodies |
| 05/22/2009 | WO2009042794A3 Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine |
| 05/22/2009 | WO2009040508A3 Methods of detection and enrichment of prpsc by immunoprecipitation and elisa |
| 05/22/2009 | WO2009035412A8 Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof |
| 05/22/2009 | WO2009028968A8 Cell marker of melanocyte cell lineage and uses thereof |
| 05/22/2009 | WO2009026574A3 Immunogenic compositions and uses thereof |
| 05/22/2009 | WO2009015087A3 Compositions and methods for treatment of trauma |
| 05/22/2009 | WO2009009424A3 Rapid generation of t cell-independent antibody responses to t cell-dependent antigens |
| 05/22/2009 | WO2008153926A4 Inhibitors of receptor tyrosine kinases and methods of use thereof |
| 05/22/2009 | WO2008152448A3 Streptococcus proteins, and their use in vaccination |
| 05/22/2009 | WO2008152446A3 Novel glycosylated peptide target in neoplastic cells |
| 05/22/2009 | WO2008127298A3 Staphylococcal enterotoxin b peptide compositions and methods of use |
| 05/22/2009 | WO2008102359A9 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 05/22/2009 | WO2008073161A3 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 05/22/2009 | WO2008051424A8 Human immune therapies using a cd27 agonist alone or in combination with other immune modulators |
| 05/22/2009 | WO2006110593A3 Biological targets for the diagnosis, treatment and prevention of cancer |
| 05/22/2009 | WO2006105479A3 Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| 05/22/2009 | WO2006072954A3 Novel il-6 polynucleotides encoding variant il-6 polypeptides and methods using same |
| 05/22/2009 | CA2706549A1 Monoclonal antibody capable of binding to anexelekto, and use thereof |
| 05/22/2009 | CA2705923A1 Antibodies to lrp6 |
| 05/22/2009 | CA2705555A1 Compositions and methods for the therapy and diagnosis of influenza |
| 05/22/2009 | CA2705509A1 Diagnosis and treatment of cancer using anti-gpr49 antibody |
| 05/22/2009 | CA2705435A1 Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
| 05/22/2009 | CA2705376A1 Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
| 05/22/2009 | CA2705357A1 Formulations for taci-immunoglobulin fusion proteins |
| 05/22/2009 | CA2705353A1 Methods of treating cancer using anti cd24 antibodies |
| 05/22/2009 | CA2705292A1 Humanized antibodies against tl1a |
| 05/22/2009 | CA2705164A1 Axl antibodies |
| 05/22/2009 | CA2704510A1 Solid compositions |
| 05/22/2009 | CA2703545A1 Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
| 05/22/2009 | CA2702971A1 Antibody production elicited by a dna vaccine delivered by electroporation |
| 05/21/2009 | US20090133135 Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases |
| 05/21/2009 | US20090131645 used to control the interaction of particular cell types with their external environment; for chronic pain; reduced side effects, long-lasting actions that do not require frequent injections or long-term catheterization; does not lead to tolerance and associated dependence |
| 05/21/2009 | US20090131639 Antibody-containing solution formulations |
| 05/21/2009 | US20090131514 Buccal, polar and non-polar sprays containing propofol |
| 05/21/2009 | US20090131347 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype |
| 05/21/2009 | US20090130762 Activation of HCV-specific T cells |
| 05/21/2009 | US20090130718 Gene site saturation mutagenesis |
| 05/21/2009 | US20090130715 Antibodies to CD40 |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/21/2009 | US20090130174 Poly (ester urethane) urea foams with enhanced mechanical and biological properties |
| 05/21/2009 | US20090130149 Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites |
| 05/21/2009 | US20090130148 Mycoplasma bovis vaccine and methods of use thereof |
| 05/21/2009 | US20090130147 Capsular polysaccharide solubilisation and combination vaccines |
| 05/21/2009 | US20090130146 Combination vaccine |
| 05/21/2009 | US20090130145 Vaccine |
| 05/21/2009 | US20090130144 Direct vaccination of the bone marrow |
| 05/21/2009 | US20090130143 Genetically modified porcine reproductive respiratory syndrome (PRRS) virus modified in the NLS-2 region, NoLS region, and/or the NES region of the nucleocapsid (N) protein such that the resultant PRRS virus is attenuated; reversion-resistant mutations; vaccines; DNA sequence encodes the infectious RNA |
| 05/21/2009 | US20090130142 Streptococcus Phocae Vaccine |
| 05/21/2009 | US20090130141 Compositions and methods for stimulating an immune response against infectious agents |
| 05/21/2009 | US20090130140 Capsular Polysaccharide Solubilisation and Combination Vaccines |
| 05/21/2009 | US20090130137 formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children; provides coverage for serotypes 6A and 19A |
| 05/21/2009 | US20090130136 Chondroitin Sulphate a Binding Domains |
| 05/21/2009 | US20090130135 Hcv vaccines |
| 05/21/2009 | US20090130134 T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof |
| 05/21/2009 | US20090130133 Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof |
| 05/21/2009 | US20090130132 Anti-caveolin-1 polyclonal antibody, and antigen peptide sequence and method for preparing the same |
| 05/21/2009 | US20090130131 Antigen-Drug Vehicle Enabling Switch From Selective Production of IgA Antibody to Production of Both of IgA and IgG Antibodies and Transnasal/Mucosal Vaccine Using the Same |
| 05/21/2009 | US20090130130 Mutant allergen(s) |
| 05/21/2009 | US20090130129 Melanoma-associated endogenous retrovirus (MERV) derived peptide sequences and their therapeutic/diagnostic use |
| 05/21/2009 | US20090130128 Antiinfective Proanthocyanidin Compounds and Methods of Use Thereof |
| 05/21/2009 | US20090130127 Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration |
| 05/21/2009 | US20090130126 Dna expression vectors |
| 05/21/2009 | US20090130125 Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer |
| 05/21/2009 | US20090130124 Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| 05/21/2009 | US20090130123 Antibodies to west nile virus polypeptides |